BigHat is a clinical stage platform AI biotechnology company accelerating antibody and biologics development through their automated discovery engine.

BigHat has built a “closed-loop" platform called Millener that integrates an automated, high-speed wet lab with advanced machine learning to accelerate antibody engineering from months to days. This tightly coupled infrastructure allows BigHat to successfully engineer sophisticated biologics formats, such as bi-specifics and ADCs, that often prove difficult for traditional discovery methods. Bighat has secured multiple partnerships with big pharma and frontier AI labs including with the likes of Lilly, JNJ, Abbvie, Merck and Amgen, as well as a wholly owned oncology pipeline that includes an ADC for gastric and colorectal cancer, and a T-cell engager for pancreatic cancer, non-small cell lung cancer and colorectal cancer.